C-7H02Samsara Therapeutics
autophagy activation, phenotypic screening, iPSCs
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-7H02
C-7H02C-7H02autophagy activation, phenotypic screening, iPSCs
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Samsara Therapeutics states that age-related decline in autophagy causes cellular damage to accumulate, and that restoring or boosting this recycling process can rejuvenate cells, erase signs of damage, and help treat currently incurable neurodegenerative and rare genetic diseases. The company also states that there is compelling evidence that boosting autophagy increases healthspan and lifespan.
SourceSamsara Therapeutics states that autophagy is the cell’s main system for recycling damaged components, that this process declines with age, and that boosting autophagy can increase healthspan and lifespan while impaired autophagy contributes to serious disease. The company presents its belief that rejuvenating cells by restoring autophagy can erase signs of cellular damage and help reverse disease, especially in neurodegenerative and rare genetic conditions, using an unbiased data-driven drug discovery approach to uncover new biology.
SourceSamsara Therapeutics states that aging is driven by conserved biochemical Hallmarks of Aging and that slowing these fundamental processes can extend healthy lifespan across species and help treat multiple age-related diseases. The company says geroscience has already shown several orthogonal ways to extend healthy lifespan in mammals, argues that industry has not yet systematically screened for geroprotective drugs, and presents its own platform as identifying, optimizing, and testing molecules that act on these aging mechanisms from human cells and yeast through animal models.
SourceSamsara Therapeutics states that aging is driven by biochemical mechanisms known as the Hallmarks of Aging, that these mechanisms are conserved across species, and that slowing aging can produce broad health benefits across multiple age-related diseases. The company argues that compounds which extend healthy lifespan in short-lived model organisms can translate across species, making geroprotective drug discovery a systematic and promising path to therapies rather than relying on narrow disease models.
Source